1.
Concurrent computed tomography-guided radioactive iodine-125 seeds percutaneous interstitial implantation and chemotherapy for treatment of cervical lymph node metastases.
Li, Z, Wang, X, Fang, K, Shi, J, Qi, X, Sun, R
Journal of cancer research and therapeutics. 2018;(Supplement):S1163-S1169
-
-
Free full text
-
Abstract
AIM: The study aimed to evaluate the effect of concurrent computed tomography (CT)-guided percutaneous interstitial implantation of iodine-125 (125I) seeds and chemotherapy on cervical lymph nodes metastasis. METHODS The prospective randomized study included 82 cases with cervical lymph nodes metastasis who were admitted to our hospital from January 2010 to June 2012. All the subjects were randomly divided into the concurrent 125I implantation and chemotherapy group (n = 48) and chemotherapy-only group (n = 34) according to the treatment strategy. The concurrent 125I implantation and chemotherapy group was treated with CT-guided 125I seeds implantation and routine chemotherapy. The routine chemotherapy included paclitaxel and cisplatin. Patients were followed up for 6 months. RESULTS In the concurrent 125I implantation and chemotherapy group, overall response rate (complete response [CR] + partial response [PR]) was 82.61% and 85.51% at 2 and 6 months posttreatment, respectively. The longest diameter of CR and PR lymph nodes was markedly decreased after treatment (P < 0.05). In the chemotherapy-only group, overall response rate was 22.45% and 10.20% at 2 and 6 months posttreatment, respectively. The number of patients with moderate to severe pain was much less in concurrent 125I implantation and chemotherapy group than that of chemotherapy-only group (4.17% vs. 17.64%; P < 0.05) at 6-month posttreatment. No treatment-related death or severe complication was reported in the two groups. CONCLUSION Concurrent CT-guided 125I seeds implantation and chemotherapy is superior to routine chemotherapy in efficacy, safety, and pain relief in patients with cervical lymph nodes metastasis.
2.
Experimental measurements of dosimetric parameters on the transverse axis of a new 125I source.
Li, Z, Fan, JJ, Palta, JR
Medical physics. 2000;(6):1275-80
Abstract
Permanent prostate implant using 125I or 103Pd sources is a common treatment choice in the management of early prostate cancer. As sources of new designs are developed and marketed for application in permanent prostate implants, it is of paramount importance that their dosimetric characteristics are carefully determined, in order to maintain a high accuracy of patient treatment. This report presents the results of experimental measurements of the dosimetric parameters performed for a newly available 125I seed source, the model MED3631-A/M source (IoGold), manufactured by North American Scientific, Inc. The measurements were performed in a large scanning water phantom, using a diode detector. The positioning of the source and the diode detector was achieved by a computer-controlled positioning mechanism in the scanning water phantom. The dose rate constant in water for the new 125I source was measured in comparison with an existing 125I source of similar design and verified using thermoluminescent dosimetry (TLD) measurement. The radial dose function values for the source were measured using the diode detector. The measurement technique and the results are compared with the dose distribution parameters for the 125I sources discussed in the AAPM TG43 report and elsewhere [Med. Phys. 26, 570-573 (1999)]. For the dose rate constant in water of the new source, it is recommended that a value of 0.950 cGy/U-hr be used based on the NIST 1985 air-kerma strength calibration standard, or 1.060 cGy/U-hr based on the 1999 NIST air-kerma strength standard. The measured radial dose function values for the MED3631-A/M source agree closely with those of the model 6702 source. It is therefore recommended that the radial dose function values for the model 6702 125I source, as recommended by the AAPM TG43 report, be adopted for the new source as well.